Arbutus Biopharma
ABUS
Market cap $676M

3.53 USD

-0.05

1.40%

At close Jun 13, 4:00 PM EDT

After hours

3.60

+0.07

1.98%

1 day

-1.40%

5 days

0.57%

1 month

10.66%

3 months

6.33%

6 months

1.44%

Year to date

7.29%

1 year

11.71%

5 years

91.85%

10 years

-66.38%

About: Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Employees: 44

Healthcare Biotechnology

0

Funds holding %

of 7,296 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

178% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 9

37% more call options, than puts

Call options by funds: $3.1M | Put options by funds: $2.26M

15% more capital invested

Capital invested by funds: $340M [Q4 2024] → $390M (+$49.6M) [Q1 2025]

8% more funds holding

Funds holding: 153 [Q4 2024] → 166 (+13) [Q1 2025]

3.43% more ownership

Funds ownership: 54.92% [Q4 2024] → 58.36% (+3.43%) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 5 [Q4 2024] → 5 (+0) [Q1 2025]

12% less repeat investments, than reductions

Existing positions increased: 46 | Existing positions reduced: 52

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$5

42%

upside

Avg. target

$5

42%

upside

High target

$5

42%

upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

Chardan Capital

Keay Nakae

42%upside

$5

Buy

Maintained

28 Mar 2025

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.

Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its RNAi therapeutic and AB-101, its oral PD-L1 inhibitor, at the European Association for the Study of the Liver (EASL) Congress 2025.

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Zacks Investment Research

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know

Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7 - 10, 2025 in Amsterdam, Netherlands.

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Zacks Investment Research

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy

Zacks Investment Research

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Here is how Arbutus Biopharma (ABUS) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?

Zacks Investment Research

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago.

Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Arbutus Biopharma is cutting its workforce by more than half as it looks to improve its financial and operational efficiency.

Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

See News Rankings

Charts implemented using Lightweight Charts™